MedTrace Logo

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

NCT00511810 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-05-27

Study results available
· View outcomes & findings →

Summary

The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD.

The primary prediction was that LCn-3 fatty acid supplementation would dose-dependently increase prefrontal cortical functional activation during sustained attention and increase regional biochemical indices of cortical metabolism and integrity concentrations in association with reductions in depressive symptoms.

Conditions

Interventions

DRUG

Low Dose Fish Oil

Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)

DRUG

High Dose Fish Oil

Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)

Sponsors & Collaborators

  • The Inflammation Research Foundation

    collaborator OTHER

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Robert McNamara, PhD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00511810 on ClinicalTrials.gov